The scope of work for the Core involves the establishment of a molecular epidemiology facility for the Cancer Center. This Core will be responsible for consulting with cancer members on molecular and genetic epidemiology and receiving, processing, barcode labeling and archiving blood, buccal, bone marrow, Guthrie blood spots, frozen and fixed tumor specimens. The Core will isolate DNA for genotyping studies and will coordinate their use with the other cores of the Cancer Center. In addition, the Core will carry out DNA adduct studies of tissue or peripheral mononuclear cells. Specifically the aims of the core are the following; To provide consultation to members concerning molecular epidemiology study design, incorporating appropriate biomarkers, advise on feasibility, sharing protocols, and questionnaires; To assist investigators carry out pilot studies. Provide field testing of protocols and biomarker assays for preliminary results for grant submissions; Specimen banking, tracking and database linkage. Provide processing, bar code labeling, storage, and customized tracking of biological specimens; cells, serum, blood, DNA, buccal cells, bone marrow, Guthrie cards, whole genome amplification (WGA) products; Special processing for genetic analyses. Carry out whole genome amplification and validation testing of buccal cells, Guthrie cards & other limited specimens and; Provide molecular analyses not available through other Cancer Center Cores. Specialized genotyping, methylation studies in fresh and paraffin embedded tissues, translocation breakpoint cloning/identification, DNA adduct measurements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-04
Application #
6694330
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-09-27
Project End
2007-01-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications